Dasatinib
- CAS No.
- 302962-49-8
- Chemical Name:
- Dasatinib
- Synonyms
- BMS-354825;CS-1968;Dasatinib;Dasaitinib;Dashatinib;NCGC00181129;25MG/100MG/1G;Dasatinib, 95+%;sprycel Dasatinib;Dasatinib Tablets
- CBNumber:
- CB4506696
- Molecular Formula:
- C22H26ClN7O2S
- Molecular Weight:
- 488.01
- MOL File:
- 302962-49-8.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/10 15:15:42
| Melting point | 275-286°C |
|---|---|
| Density | 1.408±0.06 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | Soluble in DMSO (up to 200 mg/ml). |
| pka | 10.94±0.70(Predicted) |
| form | White powder. |
| color | White or off-white |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
| InChIKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
| SMILES | S1C(C(NC2=C(C)C=CC=C2Cl)=O)=CN=C1NC1C=C(N2CCN(CCO)CC2)N=C(C)N=1 |
| CAS DataBase Reference | 302962-49-8(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS05,GHS08,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H315-H318-H351-H361fd-H372-H410 | |||||||||
| Precautionary statements | P202-P273-P280-P302+P352-P305+P351+P338-P308+P313 | |||||||||
| HS Code | 29341000 | |||||||||
| NFPA 704 |
|
Dasatinib price More Price(2)
Dasatinib Chemical Properties,Uses,Production
Description
Dasatinib, developed and marketed by Bristol Myers, is the first approved oral tyrosine kinase inhibitor which binds to multiple conformations of ABL kinase for the treatment of two leukemia indications: chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib is a highly potent, ATPcompetitive ATPcompetitive kinase inhibitor which, at nanomolar concentrations, inhibits BCR-ABL, SRC family, c-KIT, EPHA2 and PDGFR-B.
Chemical Properties
Pale-Yellow Solid
Class: non-receptor tyrosine kinase
Treatment: CML, ALL
Oral bioavailability = 14–34%
Elimination half-life = 3–5 h
Protein binding = 96%
General Description
Dasatinib is available in 20-, 50-, and 70-mg tablets fororal administration in the treatment of CML and ALL thatare Ph1 positive. Although dasatinib is more potent thanimatinib, bioavailability is much lower with values rangingbetween 14% to 34%. The agent is extensively metabolizedwith as many as 29 metabolites seen as result of oxidationby primarily CYP3A4 and phase II conjugation.The agent may act as an inhibitor of CYP3A4 andCYP2C8. Metabolism does give an active metabolite, but this accounts for only 5% of the total and is not believed tobe important for the overall activity of the agent. Dasatinibis 95% protein bound with a terminal half-life of 3 to5 hours. The majority of the drug and metabolites are eliminatedin the feces. The most common side effects are skinrash, nausea, diarrhea, and fatigue. Serious side effects includemyelosuppression appearing as neutropenia andthrombocytopenia, bleeding of the brain and GI tract, andfluid retention.
Dasatinib Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Jigs Chemical ltd | +919099003427 | Gujarat, India | 239 | 58 | Inquiry |
| Bulat Pharmaceutical Pvt Ltd | +91-8448085659 +91-8448085660 | Haryana, India | 123 | 58 | Inquiry |
| AVD pharmaceuticals Pvt Ltd | +919860835260 | Pune, India | 102 | 58 | Inquiry |
| Gonane Pharma | +91-9819380043 +91-9819380043 | NaviMumbai, India | 192 | 58 | Inquiry |
| Apotex Pharmachem India Pvt Ltd | +91-8022891034 +91-8022891000 | Karnataka, India | 109 | 58 | Inquiry |
| Alembic Pharmaceuticals Limited | +91-2652280880 +91-2652280550 | Gujarat, India | 115 | 58 | Inquiry |
| Vannsh Life Sciences Pvt Ltd | +91-4023555246 +91-9642555246 | Hyderabad, India | 15 | 58 | Inquiry |
| Shilpa Medicare Limited (SML) | +91-8532238704 +91-9320649838 | Karnataka, India | 61 | 58 | Inquiry |
| Basil Drugs AND Pharmaceuticals Pvt Ltd | +91-2249700250 +91-9619320820 | Mumbai, India | 108 | 58 | Inquiry |
| Besil Chem LLP | +91-7760252666 +91-9880731835 | Bangalore, India | 163 | 58 | Inquiry |
Related articles
- Dasatinib: Mechanism of action and Safety
- Dasatinib, a tyrosine kinase inhibitor, primarily treats chronic myeloid leukemia and Philadelphia chromosome-positive acute l....
- Mar 29，2024
- Dasatinib: BCR-ABL kinase inhibitor
- Dasatinib, known as Sprycel, is a receptor tyrosine kinase inhibitor developed by Bristol-Myers Squibb Company.
- Sep 20，2023
- Dasatinib: A second-generation BCR-ABL1 tyrosine kinase inhibitor
- Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia, but side effects may occur d....
- Sep 18，2023
302962-49-8(Dasatinib)Related Search:
1of4
chevron_right